GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 million in the first half (H1) of 2025, an annual drop of 29.70% from EGP 92.554 million

GlaxoSmithKline Egypt (GSK–Egypt) recorded EGP 59.123 million in consolidated net profits after tax and non-controlling interest in the first quarter (Q1) of 2025, against EGP 8.99 million in net losses in Q1 2024.

GlaxoSmithKline (GSK – Egypt) posted a 94.92% year-on-year (YoY) consolidated profit hike during the first nine months of 2024.

GlaxoSmithKline (GSK – Egypt) has reported a 372.87% year-on-year (YoY) surge in consolidated profits attributable to the parent company during the first half (H1) of 2024, according to financial statements filed to the Egyptian Exchange (EGX) on August 14th.

GlaxoSmithKline’s (GSK-Egypt) ordinary general meeting (OGM) has decided to distribute cash dividends of EGP 0.75 per share to shareholders for 2023 on July 22nd.

GlaxoSmithKline Egypt (GSK – Egypt) recorded EGP 8.99 million in consolidated net losses after tax and non-controlling interest in the first quarter (Q1) of 2024, against EGP 13.811 in net profits in Q1 2023.

GlaxoSmithKline (GSK – Egypt) (BIOC) posted a 91.8% year-on-year (YoY) decline in consolidated net profits after tax and non-controlling interest to EGP 60.456 million from EGP 735.379 million.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.

GlaxoSmithKline (GSK–Egypt) has amended the record date of the EGP 0.75 per share cash dividends distribution for 2022 to be June 26th, instead of July 3rd.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.

GlaxoSmithKline Egypt’s (GSK) consolidated net profits after tax and non-controlling interest soared 375.6% year on year (YoY) to EGP 735.38 million in 2022.